Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT01982890

Telomeres and T-cell Receptor Excision Circles (TRECs) From Peripheral Blood in Normal Subjects Over Time

Telomere Shortening as a Prognostic Marker in Early Inflammatory Arthritis: Establishing the Stability of Telomeres in Normal Individuals

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Université de Sherbrooke · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Accepted

Summary

The Investigators have established a cohort of patients with recent-onset inflammatory arthritis called Early Undifferentiated PolyArthritis (EUPA). This cohort was established to define novel biomarkers of poor outcomes. We want to study telomere length and T-cell Receptor Excision Circles (TREC) numbers in peripheral blood as new biomarkers. This cohort of normal controls was established to be able to define the stability over short periods of time of telomere length and TREC numbers in normal individuals, in order to compare with arthritis patients.

Detailed description

It is difficult to establish early on the prognosis of patients with recent-onset polyarthritis. We want to know if we can use the length of telomeres in peripheral blood cells at baseline as a novel prognostic marker. In order to be able to interpret our observations in arthritis patients over time, we need to compare these results with those observed in normal human controls adjusted for gender and for age groups. These patients are first screened for the presence of acute or chronic severe diseases (cancer, cardiovascular, articular, et...). They then have genomic DNA extracted from peripheral blood at Baseline and at 3 months interval for a year than annually for a total duration of 5 years. A complete blood count is collected at each blood draw. At each blood draw, the appearance of acute or chronic diseases is noted.

Conditions

Interventions

TypeNameDescription
OTHERControlNo intervention as this group is simply followed prospectively.

Timeline

Start date
2005-01-04
Primary completion
2025-02-28
Completion
2026-12-31
First posted
2013-11-13
Last updated
2025-03-25

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01982890. Inclusion in this directory is not an endorsement.